Logo image of KAPA

KAIROS PHARMA LTD (KAPA) Stock Fundamental Analysis

USA - NYSEARCA:KAPA - US48301N1046 - Common Stock

1.14 USD
-0.01 (-0.87%)
Last: 10/28/2025, 8:04:22 PM
1.11 USD
-0.03 (-2.63%)
After Hours: 10/28/2025, 8:04:22 PM
Fundamental Rating

2

Overall KAPA gets a fundamental rating of 2 out of 10. We evaluated KAPA against 534 industry peers in the Biotechnology industry. While KAPA has a great health rating, there are worries on its profitability. KAPA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KAPA has reported negative net income.
In the past year KAPA has reported a negative cash flow from operations.
KAPA Yearly Net Income VS EBIT VS OCF VS FCFKAPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -1M -2M -3M

1.2 Ratios

KAPA has a Return On Assets of -70.60%. This is in the lower half of the industry: KAPA underperforms 61.98% of its industry peers.
KAPA has a Return On Equity (-78.56%) which is in line with its industry peers.
Industry RankSector Rank
ROA -70.6%
ROE -78.56%
ROIC N/A
ROA(3y)-111.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KAPA Yearly ROA, ROE, ROICKAPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KAPA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KAPA Yearly Profit, Operating, Gross MarginsKAPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

KAPA has more shares outstanding than it did 1 year ago.
There is no outstanding debt for KAPA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KAPA Yearly Shares OutstandingKAPA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M 10M
KAPA Yearly Total Debt VS Total AssetsKAPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

KAPA has an Altman-Z score of 17.29. This indicates that KAPA is financially healthy and has little risk of bankruptcy at the moment.
KAPA's Altman-Z score of 17.29 is amongst the best of the industry. KAPA outperforms 88.76% of its industry peers.
KAPA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.29
ROIC/WACCN/A
WACCN/A
KAPA Yearly LT Debt VS Equity VS FCFKAPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

A Current Ratio of 7.16 indicates that KAPA has no problem at all paying its short term obligations.
KAPA has a better Current ratio (7.16) than 70.22% of its industry peers.
A Quick Ratio of 7.16 indicates that KAPA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.16, KAPA is doing good in the industry, outperforming 70.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.16
Quick Ratio 7.16
KAPA Yearly Current Assets VS Current LiabilitesKAPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for KAPA have decreased strongly by -62.44% in the last year.
EPS 1Y (TTM)-62.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-319.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KAPA will show a very negative growth in Earnings Per Share. The EPS will decrease by -35.42% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-20%
EPS Next 2Y-36.01%
EPS Next 3Y-35.42%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KAPA Yearly EPS VS EstimatesKAPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KAPA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KAPA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KAPA Price Earnings VS Forward Price EarningsKAPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KAPA Per share dataKAPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

KAPA's earnings are expected to decrease with -35.42% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-36.01%
EPS Next 3Y-35.42%

More info and screens

0

5. Dividend

5.1 Amount

KAPA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KAIROS PHARMA LTD

NYSEARCA:KAPA (10/28/2025, 8:04:22 PM)

After market: 1.11 -0.03 (-2.63%)

1.14

-0.01 (-0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/dmh
Earnings (Next)N/A N/A
Inst Owners1.11%
Inst Owner Change0%
Ins Owners32.72%
Ins Owner Change0%
Market Cap23.64M
Revenue(TTM)N/A
Net Income(TTM)-4711000
Analysts82.22
Price Target8.5 (645.61%)
Short Float %2.15%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.73%
Min EPS beat(2)-56.86%
Max EPS beat(2)-42.6%
EPS beat(4)0
Avg EPS beat(4)-153.44%
Min EPS beat(4)-390.2%
Max EPS beat(4)-42.6%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.12%
EPS NY rev (1m)0%
EPS NY rev (3m)15.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.94
P/tB 4.04
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0
BVpS0.29
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.6%
ROE -78.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-111.42%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.16
Quick Ratio 7.16
Altman-Z 17.29
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-319.29%
EPS Next Y-20%
EPS Next 2Y-36.01%
EPS Next 3Y-35.42%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-677.2%
EBIT Next 3Y-180.07%
EBIT Next 5YN/A
FCF growth 1Y-4982.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4982.72%
OCF growth 3YN/A
OCF growth 5YN/A

KAIROS PHARMA LTD / KAPA FAQ

What is the ChartMill fundamental rating of KAIROS PHARMA LTD (KAPA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to KAPA.


What is the valuation status for KAPA stock?

ChartMill assigns a valuation rating of 0 / 10 to KAIROS PHARMA LTD (KAPA). This can be considered as Overvalued.


How profitable is KAIROS PHARMA LTD (KAPA) stock?

KAIROS PHARMA LTD (KAPA) has a profitability rating of 0 / 10.


What is the expected EPS growth for KAIROS PHARMA LTD (KAPA) stock?

The Earnings per Share (EPS) of KAIROS PHARMA LTD (KAPA) is expected to decline by -20% in the next year.